Skip to content
approvedHormone Regulation

Goserelin

Also known as: Zoladex, Goserelin Acetate

Goserelin is a synthetic GnRH agonist decapeptide delivered as a biodegradable subcutaneous implant (Zoladex). FDA-approved for prostate cancer, breast cancer, endometriosis, and endometrial thinning prior to ablation surgery, it is unique among GnRH agonists for its implant delivery system — a small cylindrical depot injected under the anterior abdominal wall skin that slowly releases goserelin over 1 or 3 months. Goserelin achieves medical castration by suppressing the hypothalamic-pituitary-gonadal axis, and is one of the few GnRH agonists with an approved indication for premenopausal breast cancer.

4 cited references·5 researched benefits

Quick Answer

Goserelin (Zoladex) is a GnRH agonist delivered as a biodegradable subcutaneous implant, FDA-approved for prostate cancer, breast cancer, endometriosis, and endometrial thinning. Its unique implant formulation releases the drug over 1 or 3 months, providing convenient sustained hormone suppression. It is one of the few GnRH agonists indicated for premenopausal breast cancer as ovarian suppression therapy.

Key Facts

Mechanism
Goserelin is a decapeptide analog of native GnRH with a D-serine(tBu) substitution at position 6 and an azagly-NH₂ replacement at position 10, conferring resistance to enzymatic degradation and increased receptor binding potency. The Zoladex implant is a biodegradable cylinder of D,L-lactide-glycolide copolymer that is injected subcutaneously in the anterior abdominal wall using a pre-loaded syringe. The polymer matrix slowly degrades, providing sustained goserelin release. Initial administration stimulates a transient flare of LH, FSH, and sex steroids for 1-2 weeks. Continued drug release causes pituitary GnRH receptor downregulation, suppressing gonadotropins and reducing testosterone or estradiol to castrate/postmenopausal levels within 2-4 weeks.
Research Status
approved
Half-Life
~4-5 hours (implant provides sustained release over 1-3 months)
Molecular Formula
C₅₉H₈₄N₁₈O₁₄
Primary Use
Hormone Regulation
Table of Contents

Benefits

  • Treats advanced prostate cancer with equivalent efficacy to orchiectomy — castrate testosterone levels achieved in over 95% of patientsstrong
  • Ovarian suppression for premenopausal breast cancer — FDA-approved, improves outcomes when combined with tamoxifen or aromatase inhibitors in hormone receptor-positive diseasestrong
  • Relieves endometriosis-associated pain — significant reduction in dysmenorrhea, dyspareunia, and pelvic pain in controlled trialsstrong
  • Convenient implant delivery — single injection every 1 or 3 months eliminates daily dosing or monthly intramuscular injectionsstrong
  • Endometrial thinning prior to ablation — FDA-approved to thin the endometrium before surgical ablation for dysfunctional uterine bleedingstrong

Dosage Protocols

RouteDosage RangeFrequencyNotes
Subcutaneous implant (prostate cancer)3.6 mg (1-month) or 10.8 mg (3-month)Every 28 days or every 12 weeksZoladex implant injected into anterior abdominal wall subcutaneous tissue. Antiandrogen flare protection recommended for first 2-4 weeks. The 10.8 mg formulation offers 3-month dosing convenience.
Subcutaneous implant (breast cancer)3.6 mgEvery 28 daysUsed for ovarian suppression in premenopausal hormone receptor-positive breast cancer. Typically combined with tamoxifen or an aromatase inhibitor. Duration per oncology protocol (typically 2-5 years).
Subcutaneous implant (endometriosis)3.6 mgEvery 28 days for up to 6 monthsAdd-back hormone therapy recommended. Treatment limited to 6 months due to bone density concerns. May be repeated after a recovery interval.
Subcutaneous implant (endometrial thinning)3.6 mg (1 or 2 implants)1-2 implants 4 weeks apart, with surgery 2-4 weeks after last implantFDA-approved for endometrial thinning prior to ablation for dysfunctional uterine bleeding.

Medical disclaimer

Dosage information is provided for educational reference only. Always follow your prescriber's instructions and consult a qualified healthcare provider before starting any peptide protocol.

Side Effects

  • Hot flashes — the most common side effect, occurring in 55-80% of patients across all indicationscommon
  • Injection site reactions — pain, bruising, and rarely implant migration at the abdominal wall injection sitecommon
  • Decreased bone mineral density — clinically significant bone loss with prolonged use; DEXA monitoring recommended for treatment exceeding 6 monthsserious
  • Testosterone flare — initial 1-2 week surge in prostate cancer patients can worsen bone pain, urinary obstruction, and spinal cord compressionserious
  • Sexual dysfunction — decreased libido, erectile dysfunction (men), and vaginal dryness (women) due to sex hormone suppressioncommon
  • Mood changes and depression — reported in 5-15% of patients; may include emotional lability and irritabilitycommon
  • Tumor flare with breast cancer — transient worsening of symptoms or disease markers possible during initial treatment in breast cancer patientsserious

Frequently Asked Questions

How is the Zoladex implant administered?
Zoladex comes in a pre-loaded syringe with a 16-gauge needle. It is injected subcutaneously into the anterior abdominal wall, below the navel. The procedure takes about 30 seconds and is performed in a clinic. After injection, the biodegradable polymer implant slowly dissolves over 1-3 months, continuously releasing goserelin. Local anesthesia is not typically required but can be used. Common injection site issues include minor pain, bruising, and a small palpable lump that resolves as the implant degrades.
Why is goserelin used for breast cancer?
Goserelin suppresses ovarian estrogen production in premenopausal women, which is critical because approximately 75% of breast cancers are hormone receptor-positive and fueled by estrogen. The landmark SOFT and TEXT trials demonstrated that ovarian suppression with goserelin plus tamoxifen or an aromatase inhibitor significantly improves disease-free survival compared to tamoxifen alone in premenopausal women with hormone receptor-positive breast cancer, particularly in higher-risk patients. Goserelin is one of the few GnRH agonists with an FDA-approved breast cancer indication.
Does goserelin cause a testosterone flare like leuprolide?
Yes. Like all GnRH agonists, goserelin causes an initial testosterone surge during the first 1-2 weeks of treatment. In prostate cancer patients, this can temporarily worsen bone pain, urinary symptoms, and rarely spinal cord compression. The flare is managed by starting an antiandrogen (such as bicalutamide 50 mg daily) before or at the same time as the first Zoladex implant and continuing for 2-4 weeks. Patients who cannot tolerate the flare risk may be better suited to a GnRH antagonist like degarelix.
Can the Zoladex implant be removed after insertion?
The Zoladex implant is designed to be biodegradable and fully absorbed by the body. It cannot be easily removed once injected, unlike the histrelin (Vantas/Supprelin LA) implant, which is a non-biodegradable rod that can be surgically removed. If discontinuation is needed, treatment is simply stopped by not placing the next implant. The remaining depot will be absorbed and drug release will cease within a few weeks. The irretrievable nature of the implant should be discussed with patients before first administration.
How long does it take for goserelin to work for endometriosis?
Goserelin begins suppressing estrogen within 2-3 weeks of the first implant. Most women notice symptom improvement within 4-8 weeks, with maximum pain relief typically achieved by the second or third monthly implant. Complete amenorrhea (cessation of periods) usually occurs by the second month. After stopping treatment, menses typically return within 8-12 weeks and endometriosis symptoms may gradually recur, as the underlying disease is not cured by temporary hormonal suppression.

References

  1. 1
    Zoladex (goserelin acetate implant): clinical pharmacology and therapeutic efficacy in prostate cancer(1989)PubMed ↗
  2. 2
    GnRH agonists and antagonists in prostate cancer: a comparative review(2004)PubMed ↗
  3. 3
    Adjuvant ovarian suppression with goserelin in premenopausal breast cancer: the SOFT trial(2015)PubMed ↗
  4. 4
    Goserelin depot in the treatment of endometriosis: assessment of efficacy and tolerability(1996)PubMed ↗

Latest Research

Last updated: 2026-02-19